TWIK-2 channel deficiency leads to pulmonary hypertension through a rho-kinase-mediated process

Lavannya M Pandit1, Eric E Lloyd2, Julia O Reynolds2

  • 1From the Departments of Internal Medicine (L.M.P., X.H.T.W., R.M.B.), Anesthesiology (E.E.L., R.M.B.), Cardiovascular Research Institute, Department of Molecular Physiology and Biophysics (J.O.R., C.R., X.H.T.W., R.M.B.), Baylor College of Medicine, and Department of Microbiology and Immunology (W.S.L.), The University of Texas Medical Branch lpandit@bcm.edu.

Insights

TWIK-2 channel deficiency causes pulmonary hypertension in mice by 20 weeks of age. This condition involves vascular remodeling and Rho-kinase activation, suggesting TWIK-2

Area of Science:

  • Cardiovascular Biology
  • Ion Channel Physiology
  • Pulmonary Hypertension Research

Background:

  • TWIK-2 (KCNK6) is a 2-pore domain potassium channel highly expressed in the vascular system.
  • Pulmonary hypertension is a serious condition characterized by high blood pressure in the pulmonary arteries.

Purpose of the Study:

  • To investigate the role of TWIK-2 in the development of pulmonary hypertension.
  • To determine if TWIK-2 deficiency leads to pulmonary vascular remodeling and altered vascular contractility.

Main Methods:

  • Utilized TWIK-2 knockout mice and wildtype littermates for comparative studies.
  • Measured mean right ventricular systolic pressures and assessed pulmonary vascular remodeling.
  • Evaluated pulmonary artery contractility and the effects of Rho-kinase inhibitors.

Main Results:

  • TWIK-2 knockout mice developed significantly elevated right ventricular systolic pressures by 20 weeks of age compared to wildtype.
  • Pulmonary hypertension in knockout mice was associated with increased vessel wall area and enhanced contractile responses.
  • Inhibition of Rho-kinase activity with Y27632 or fasudil ameliorated hypertension and vascular remodeling.

Conclusions:

  • TWIK-2 deficiency leads to the development of pulmonary hypertension between 8 and 20 weeks of age in mice.
  • The mechanism involves Rho-kinase activation and pulmonary vascular remodeling.
  • Downregulation of TWIK-2 may be a contributing factor to pulmonary hypertension pathogenesis.

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
892
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
15.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
686
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.1K